Tempus AI (NASDAQ:TEM) & Omnicell (NASDAQ:OMCL) Financial Survey

Tempus AI (NASDAQ:TEM) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Tempus AI and Omnicell’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tempus AI	-18.45%	-73.21%	-13.78%
Omnicell	2.01%	4.27%	2.44%

Risk & Volatility

Tempus AI has a beta of 4.86, meaning that its share price is 386% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Insider & Institutional Ownership

24.2% of Tempus AI shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 26.3% of Tempus AI shares are owned by company insiders. Comparatively, 2.5% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Tempus AI and Omnicell”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempus AI	$693.40 million	17.93	-$705.81 million	($1.19)	-60.13
Omnicell	$1.18 billion	1.36	$12.53 million	$0.43	82.98

Omnicell has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Tempus AI and Omnicell, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempus AI	1	8	7	0	2.38
Omnicell	1	2	3	0	2.33

Tempus AI presently has a consensus target price of $79.85, indicating a potential upside of 11.58%. Omnicell has a consensus target price of $42.00, indicating a potential upside of 17.71%. Given Omnicell’s higher possible upside, analysts plainly believe Omnicell is more favorable than Tempus AI.

Summary

Omnicell beats Tempus AI on 9 of the 14 factors compared between the two stocks.

About Tempus AI

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.

About Omnicell

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.